Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma

Oncotarget

Volumn 7, Issue 12, 2016, Pages 13372-13387

  Kim, Jung Ho ^a   Bae, Jeong Mo ^b   Song, Young Seok ^b   Cho, Nam Yun ^b   Lee, Hye Seung ^c   Kang, Gyeong Hoon ^b  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Colorectal cancer; EPCAM; Immunohistochemistry; Lynch syndrome; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; PROTEIN MSH2; EPCAM PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; COHORT ANALYSIS; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; CPG ISLAND METHYLATOR PHENOTYPE; DISEASE FREE SURVIVAL; DNA METHYLATION; EPCAM GENE; FEMALE; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR INVASION; COLLOID CARCINOMA; COLORECTAL TUMOR; FOLLOW UP; GENETICS; LYMPH NODE METASTASIS; MEDULLARY CARCINOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; SIGNET RING CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA, MUCINOUS; BIOMARKERS, TUMOR; CARCINOMA, MEDULLARY; CARCINOMA, SIGNET RING CELL; COLORECTAL NEOPLASMS; EPITHELIAL CELL ADHESION MOLECULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84971671412     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5618     Document Type: Article

References (26)

1. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev. 2012; 38:68-75.
2. Simon M, Stefan N, Pluckthun A, Zangemeister-Wittke U. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opin Drug Deliv. 2013; 10:451-468.
3. Kloor M, Voigt AY, Schackert HK, Schirmacher P, von Knebel Doeberitz M, Blaker H. Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. J Clin Oncol. 2011; 29:223-227.
4. Huth C, Kloor M, Voigt AY, Bozukova G, Evers C, Gaspar H, Tariverdian M, Schirmacher P, von Knebel Doeberitz M, Blaker H. The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors. Mod Pathol. 2012; 25:911-916.
5. Musulen E, Blanco I, Carrato C, Fernandez-Figueras MT, Pineda M, Capella G, Ariza A. Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification. Hum Pathol. 2013; 44:412-416.
6. Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken JH, Nagtegaal ID. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol. 2007; 20:221-232.
7. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 2010; 103:382-390.
8. Goossens-Beumer IJ, Zeestraten EC, Benard A, Christen T, Reimers MS, Keijzer R, Sier CF, Liefers GJ, Morreau H, Putter H, Vahrmeijer AL, van de Velde CJ, Kuppen PJ. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer. 2014; 110:2935-2944.
9. Kim JH, Bae JM, Kim KJ, Rhee YY, Kim Y, Cho NY, Lee HS, Chang MS, Kang GH. Differential Features of Microsatellite-Unstable Colorectal Carcinomas Depending on EPCAM Expression Status. Korean J Pathol. 2014; 48:276-282.
10. Ligtenberg MJ, Kuiper RP, Geurts van Kessel A, Hoogerbrugge N. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam Cancer. 2013; 12:169-174.
11. Tutlewska K, Lubinski J, Kurzawski G. Germline deletions in the EPCAM gene as a cause of Lynch syndrome - literature review. Hered Cancer Clin Pract. 2013; 11:9.
12. Kim JH, Kang GH. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol. 2014; 20:4230-4243.
13. Bae JM, Kim MJ, Kim JH, Koh JM, Cho NY, Kim TY, Kang GH. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Arch. 2011; 459:55-63.
14. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010; 1:651-661.
15. Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, Trezzi R, De Dosso S, Vlajnic T, Frattini M, Lugli A. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol. 2010; 16:4823-4831.
16. Rogers AC, Gibbons D, Hanly AM, Hyland JM, O'Connell PR, Winter DC, Sheahan K. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol. 2014; 27:156-162.
17. Kim JH, Kim KJ, Rhee YY, Oh S, Cho NY, Lee HS, Kang GH. Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer. Mod Pathol. 2014; 27:443-453.
18. Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer. 2013; 109:1004-1012.
19. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58:5248-5257.
20. Bosman FT, World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of the digestive system. (Lyon: International Agency for Research on Cancer). 2010.
21. Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, Matsukuma S, Kanai T, Kurihara H, Ozawa K, Yoshimura K, Bekku S. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004; 127:385-394.
22. Spizzo G, Gastl G, Obrist P, Fong D, Haun M, Grunewald K, Parson W, Eichmann C, Millinger S, Fiegl H, Margreiter R, Amberger A. Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett. 2007; 246:253-261.
23. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000; 28:E32.
24. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006; 55:1000-1006.
25. Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med. 2008; 132:1657-1665.
26. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 2009; 455:485-494.